Search the Newsreel

Silence Therapeutics (SLN) Drops 9.7% as Bearish Momentum Persists - Take Profit Levels

Silence Therapeutics (SLN) to Post Earnings on Thursday

ADAR1 Capital Management LLC Buys 148,514 Shares of Silence Therapeutics PLC Sponsored ADR $SLN

Silence Therapeutics Plc (SLN) Q4 2024 Earnings: Positive EPS Reported Despite No Revenue; Stock Declines - Profit Growth Outlook

Silence Therapeutics PLC (SLN) Institutional Confidence

The article analyzes the institutional confidence in Silence Therapeutics PLC (SLN), noting an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 0.85% quarter-over-quarter to 40.59%. Steven Cohen is …

Silence Therapeutics PLC (SLN) Financial Health: Profitability & Balance Sheet Analysis

Silence Therapeutics PLC (SLN) has a current financial score of 6.66, ranking 233 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. Despite this, its latest quarterly revenue increased by 197.18% year-over-year to 422.00K, …

Silence Therapeutics (NASDAQ:SLN) Sees Large Volume Increase - Still a Buy?

Silence Therapeutics PLC (SLN) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Silence Therapeutics PLC (SLN), noting its current earnings forecast score of 8.00 and ranking in the Biotechnology & Medical Research industry. It details analyst ratings, with a strong "Buy" trend and an average price target of $30.00, …

Silence Therapeutics PLC (SLN) Cash Flow

This article provides a detailed cash flow statement for Silence Therapeutics PLC (SLN), covering quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow metrics and answers frequently asked questions about the company's financial performance, including operating cash …

Silence Therapeutics PLC (SLN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Silence Therapeutics PLC (SLN), outlining major shareholders, both individual and institutional, and their respective holdings. It also categorizes shareholders by type and provides a historical view of institutional shareholding over recent quarters. The report includes recent changes …

Silence Therapeutics Plc - American Depository Share Revenue Breakdown – NASDAQ:SLN

Silence Therapeutics Plc (NASDAQ: SLN) reported a significant decrease in its top-performing segment, Research Collaboration - AstraZeneca, generating only $559.00K USD last year compared to $17.96M USD the previous year. The United Kingdom was the primary contributor to this revenue. The article provides a …

SLN|Silence Therapeutics PLC|Price:14.544|Chg%:-0.176

Silence Therapeutics PLC (SLN) has a TradingKey Stock Score indicating stable fundamentals, high growth potential, and a 'fairly valued' assessment within the Biotechnology & Medical Research industry. Despite strong institutional ownership and multiple 'Buy' ratings from analysts with a high target price, technical indicators …

Silence Therapeutics PLC (SLN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Silence Therapeutics PLC (SLN) focusing on its dividend and stock split history. It states that the company has distributed a total of $0.00 USD in dividends over the past five years, indicating no recent payouts. The article lists …

Silence Therapeutics PLC (SLN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Silence Therapeutics PLC (SLN) as of July 24, 2026. The company's valuation score is 7.80, ranking it 199 out of 386 in the Biotechnology & Medical Research industry. Key financial ratios like P/E, P/B, P/S, and P/CF …

Silence Therapeutics PLC (SLN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Silence Therapeutics PLC (SLN), noting that key financial data for FY2025, FY2024, and specific quarters of FY2024 and FY2023 have not yet been disclosed by the company. The visible regional revenue data indicates that 100% of the …

Silence Therapeutics (NASDAQ:SLN) Reaches New 12-Month High - Time to Buy?

Silence Therapeutics (NASDAQ:SLN) Stock Price Up 6.9% - Here's Why

ETFs Investing in Silence Therapeutics PLC Sponsored ADR Stocks

This article lists various ETFs that hold shares of Silence Therapeutics PLC Sponsored ADR (SLN). It provides a detailed table including each ETF's market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total …

Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last?

Silence Therapeutics (SLN) saw its shares rise 7.2% due to investor optimism about its RNA interference pipeline, upcoming clinical data, and the long-term potential of its lead candidate, divesiran. The company anticipates topline results for its phase II SANRECO study in August 2026 and …

SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know

Shares of Silence Therapeutics (SLN) have surged 107% in the past six months, driven by investor optimism surrounding its RNA interference (siRNA) pipeline. The company's lead candidate, divesiran, for polycythemia vera, is showing promising results in clinical trials, with top-line data anticipated in Q3 …

Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?

Why Is Silence Therapeutics Stock Soaring Wednesday? - Silence Therapeutics (NASDAQ:SLN)

With Silence Therapeutics Up 24%, Insider Buyers Count Their Returns

Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?

Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive

Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

Silence Therapeutics Plc (SLN) Stock Price, News & Analysis